Analyzing Enzalutamide Patient-Reported Outcomes and QOL in the EMBARK Trial With Stephen Freedland, MD
Expert Perspectives · Keira Smith · 2024-06-28
At this year’s American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland sat down to discuss two of his presentations which investigated patient-reported outcomes and quality of life (QOL) with enzalutamide for prostate cancer, including:
- An overview of the EMBARK trial and how it led to the approval of enzalutamide for prostate cancer
- The results found in his team’s post-hoc analysis evaluating the impact of enzalutamide treatment suspension on health-related QOL
- The results of their post-hoc analysis investigating sexual-activity patient-reported outcomes
- How the findings of both of these studies can be used for informing prescribing of enzalutamide and patient counseling
- Other ongoing and future analyses aiming to optimize the use of enzalutamide for patients with prostate cancer
- And more!
About Dr. Freedland
Stephen Freedland, MD, is Director of the Center for Integrated Research in Cancer and Lifestyle and Associate Director for Education and Training at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute in Los Angeles. As well, he is the Warschaw Robertson Law Families Chair in Prostate Cancer and a Professor in the Department of Urology at Cedars-Sinai. He holds a Staff Physician appointment at the Durham VA Medical Center in Durham, North Carolina. Dr. Freedland has published over 700 articles and served on numerous AUA and ASCO guideline panels for prostate cancer. His research interests include the role of diet, lifestyle, and obesity in cancer, cancer health disparities, and cancer risk stratification.